Finland’s PDT+TTF glioblastoma combo extends control, but device gatekeeping favors elite centers.Finland is testing a two-pronged attack on one of the toughest brain cancers.

It’s not “one miracle”—it’s stacking physics on top of biology.

Photodynamic therapy (PDT) uses a light-activated drug to create toxic oxygen species inside tumor tissue.

Tumor Treating Fields (TTF) uses alternating electric fields to disrupt cancer cell division.

Together, the idea is to weaken the tumor’s defenses from two angles at once. Source

Controversy: both tools depend on specialized devices, contracts, and trained centers.

If only a few hospitals get the tech, “standard of care” becomes a postcode lottery.

Device companies can quietly decide access through pricing and distribution.

For the US/UK/Canada, glioblastoma patients can’t wait years for “center expansion.”

If a combo improves outcomes, your system needs capacity—not just headlines.

If a therapy is device-locked, is it healthcare—or a membership program for the lucky few? ⚡

📊 Source: Frontiers in Oncology, Feb 2025

#Glioblastoma #PhotodynamicTherapy #TumorTreatingFields #NeuroOncology #MedicalDevices #AccessInequality #CancerTech #FinlandResearch #DevicePolicy #ClinicalOncology